Molecular Cancer Therapeutics
The Journal of Cancer Drug Discovery & Preclinical Development
December 2012 • Volume 11 • Number 12

Contents

Highlights of This Issue 2547

REVIEW
2549 It’s About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy
Jason R. Westin and Razelle Kurzrock

THERAPEUTIC DISCOVERY
2556 Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel
Diana M. Cittelly, Irina Dimitrova, Erin N. Howe, Dawn R. Cochrane, Annie Jean, Nicole S. Spoelstra, Miriam D. Post, Xian Lu, Russell R. Broaddus, Monique A. Spellman, and Jennifer K. Richer

2566 Dual Systemic Tumor Targeting with Ligand-Directed Phage and Grp78 Promoter Induces Tumor Regression
Azadeh Kia, Justyna M. Przystal, Nastasia Nianiaris, Nicholas D. Mazarakis, Paul J. Mintz, and Amin Hajitou

2578 DLL4-Fc, an Inhibitor of DLL4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity

PRECLINICAL DEVELOPMENT
2600 RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma
Yuji Shimura, Junya Kuroda, Masaki Ri, Hisao Nagoshi, Mio Yamamoto-Sugitani, Tsutomu Kobayashi, Miki Kiyota, Ryuko Nakayama, Shinsuke Mizutani, Yoshiaki Chinen, Natsumi Sakamoto, Yosuke Matsumoto, Shigeo Horiike, Yukimasa Shiotzu, Shinsuke Iida, and Masafumi Taniwaki

2610 Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Ping Yi, Arisa Higa, Said Taouji, Mariana G. Bexiga, Esther Marza, Daniela Arma, Claire Castain, Brigitte Le Bail, Jeremy C. Simpson, Jean Rosenbaum, Charles Balbaut, Paulette Bioulac-Sage, Jean-Frédéric Blanc, and Eric Chevet

2633 Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
Jaime Acquaviva, Donald L. Smith, Jim Sang, Julie C. Friedland, Suqin He, Manuel Sequeira, Chaohua Zhang, Yumiko Wada, and David A. Proia

2644 BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
Niranjan Awasthi, Changhua Zhang, Winston Ruan, Margaret A. Schwarz, and Roderich E. Schwarz

2654 Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma
Joanna Keating, Maria Tsoli, Andrew R. Hallahan, Wendy J. Ingram, Michelle Haber, and David S. Ziegler
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
Matthias Friedrich, Tobias Raum, Ralf Lutterbuese, Markus Voelkel, Petra Deegen, Doris Rau, Roman Kisichel, Patrick Hoffmann, Christian Brandl, Joachim Schuhmacher, Peter Mueller, Ricarda Finnern, Melanie Fuergut, Dieter Zopf, Jerry W. Slootstra, Patrick A. Baueuerle, Benno Rattel, and Peter Kufer

Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts
Angela Romanelli, Anderson Clark, Franck Assayag, Sophie Chateau-Joubert, Marie-France Poupon, Jean-Luc Servel, Jean-Jacques Fontaine, Xiaohong Liu, Edward Spooner, Samantha Goodstal, Patricia de Cremou, Ivan Bieche, Didier Decaudin, and Elisabeta Marangoni

Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

Development of Gene Expression-Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors
Jerome Moreaux, Thierry Rem, Wim Leonard, Jean-Luc Veyrune, Guilhem Requinand, Hartmut Goldschmidt, Dirk Hose, and Bernard Klein

Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
James S. Wilmott, Varsha Tembe, Julie R. Howle, Raghwa Sharma, John F. Thompson, Helen Rizos, Roger S. Lo, Richard F. Keeford, Richard A. Scodyer, and Georgina V. Long

Acknowledgment to Reviewers

ABOUT THE COVER

Olfactomedin-like 3 (Olfml3), a proangiogenic cue and a BMP4 agonist, is produced by both tumor endothelial cells and accompanying pericytes and deposited in the perivascular compartment. Blocking Olfml3 regresses the tumor vasculature, decreases pericyte coverage, and inhibits the progression of tumors. Olfml3 blockade provides an alternative strategy to control tumor growth by targeting a single molecule that affects two distinct cell types within the tumor microenvironment. For details, see article by Miljkovic-Licina and colleagues on page 2588.
Molecular Cancer Therapeutics

11 (12)


Updated version

Access the most recent version of this article at:
http://mct.aacrjournals.org/content/11/12

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.